Roche Diagnostics Licenses Melting Curve Analysis and SYBR Green Techniques to Takara Bio
Covered in the agreement are reagents and or methods using SYBR Green I technology and melting curve analysis for real time PCR. This valuable intellectual property portfolio has been extensively licensed by Roche in cooperation with Idaho Technology, Inc.
"By licensing the PCR technique we contribute to the further development of this technology in the life science research field," states Manfred Baier, Head of Roche Applied Science, a business area of Roche Diagnostics.
The melting curve analysis is a technique for analysis of PCR products. After PCR, the resulting PCR product is slowly heated. Each doublestranded DNA has its own specific melting temperature (Tm), which is defined as the temperature at which 50% of the DNA becomes single stranded. By measurement of Tm, the DNA can be easily identified.
About Takara Bio
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is a worldstandard in gene therapy protocols.
In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cellbased therapy, and agricultural biotechnology; and is committed preventing disease and improving the quality of life for all people through the use of biotechnology. More information on Takara-Bio is available at www.takara-bio.com.
Roche Diagnostics Deutschland GmbH
Headquartered in Basel, Switzerland, Roche is a leader in researchfocused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in invitro diagnostics, tissuebased cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Press releases you might also be interested in
Weitere Informationen zum Thema "Forschung und Entwicklung":
Die Maschine lernt nie aus
Künstliche Intelligenz (KI) ist ein neues Stichwort im Beschaffungsmanagement. Aber was kann sie wirklich leisten? Technologisch hat KI schon seit längerem einen hohen Reifegrad erreicht, doch erst die heute verfügbaren großen Datenmengen und die hohe und günstige Rechenpower ermöglichen entsprechende Anwendungen für das ProcurementWeiterlesen